Non-Alcoholic Fatty Liver Disease, Atherosclerosis, and Cardiovascular Disease in Asia

The prevalence of non-alcoholic fatty liver disease (NAFLD) is estimated to increase to over half of the adult population by 2040 globally. Since the final diagnosis of NAFLD is made by a liver biopsy, several non-invasive approaches have been developed and validated to define NAFLD and evaluate NAF...

Full description

Saved in:
Bibliographic Details
Published in:Reviews in cardiovascular medicine 2023-06, Vol.24 (6), p.173
Main Authors: Lim, Yohwan, Jeong, Seogsong, Hong, Myunghee, Han, Hyun Wook
Format: Article
Language:English
Subjects:
cardiovascular disease
metabolic dysfunction-associated fatty liver disease
non-alcoholic fatty liver disease
non-alcoholic steatohepatitis
Review
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The prevalence of non-alcoholic fatty liver disease (NAFLD) is estimated to increase to over half of the adult population by 2040 globally. Since the final diagnosis of NAFLD is made by a liver biopsy, several non-invasive approaches have been developed and validated to define NAFLD and evaluate NAFLD-associated diseases. Presently, NAFLD has been identified as an important and independent risk factor for developing several extrahepatic diseases, including atherosclerosis, cardiovascular disease (CVD), diabetes, and dementia. This review discusses current findings of up-to-date literature regarding the effects of NAFLD on the risk of atherosclerosis and CVD in Asia along with potential underlying biological mechanisms and therapeutic approaches to lower the NAFLD-related CVD risk. We further focus on the difference between NAFLD and metabolic dysfunction-associated fatty liver disease (MAFLD) on the risk of CVD and its implication by comparing the risk of NAFLD and MAFLD.
ISSN:1530-6550
2153-8174
1530-6550
DOI:10.31083/j.rcm2406173